Drugs News and Research

RSS

Novel drug delivery device can treat diabetes-related retinal damage

A team of engineers and scientists at the University of British Columbia has developed a device that can be implanted behind the eye for controlled and on-demand release of drugs to treat retinal damage caused by diabetes.

1 Jul 2011

Novel cerebrospinal fluid proteins found in greater concentrations in Alzheimer's patients

Researchers at the Sahlgrenska Academy, University of Gothenburg, have identified a series of novel proteins in human cerebrospinal fluid. The proteins, which carry specific sugar molecules, are found in greater concentrations in patients with dementia caused by Alzheimer's disease than in patients with dementia caused by other diseases. This gives hope for new forms of treatment in the future.

1 Jul 2011

The Max Cure Foundation, SWCRF partner to fund pediatric cancer research

The Max Cure Foundation and the Samuel Waxman Cancer Research Foundation have partnered to establish a fund in pediatric cancer research. With that goal in mind, the two Foundations are proud to announce the award of $100,000 to Erwin G. Van Meir, Ph.D., of Emory University School of Medicine in Atlanta.

1 Jul 2011

Amylin behaves when guarded by zinc

In type 2 diabetes, a protein called amylin forms dense clumps that shut down insulin-producing cells, wreaking havoc on the control of blood sugar. But zinc has a knack for preventing amylin from misbehaving.

1 Jul 2011

Using American diplomacy to fight NTDs

In a PLoS Neglected Tropical Diseases editorial, Peter Hotez of the Sabin Vaccine Institute outlines the diplomatic benefits of fighting NTDs in developing countries. He discusses why the State Department and USAID should be involved and outlines how they could work to expand NTD control.

1 Jul 2011

New analytical approach can organize large amounts of varied cancer genetic data

The technology that allows scientists to profile the entire genome of individual tumors offers new hope for discovering ways to select the best treatment for each patient's particular type of cancer. However, these profiles produce huge amounts of data, and the volume alone creates unique analytical problems.

1 Jul 2011

Ovarian cancer molecular updates

In a new study a genetic mutation was found in the most common form of ovarian cancer. This according to the US scientists could pave the way for a more effective treatment of the disease. The detailed genetic map already helped scientists identify existing drugs with the potential for treating the mutations found in ovarian cancer tumors and also identified mutations that could respond to new drugs.

1 Jul 2011

New clot busting drug approved in UK

The National Institute for Clinical Excellence (Nice), UK, has approved a new drug which one study has suggested could reduce the risk of death from a second heart attack by 20 per cent. The drug is manufactured by AstraZeneca as Brilique. It works by maintaining cardiac blood flow and stopping new blood clots from forming.

1 Jul 2011

Multinational drug companies' scam

In an Al Jazeera opinion piece, the first in a two-part series, Khadija Sharife, a journalist and visiting scholar at the Center for Civil Society, examines how multinational drug companies control markets.

1 Jul 2011

Some generic anti-epilepsy drugs may not be effective

30 Jun 2011

Premature ejaculation treatment market to reach over $1.3 billion by 2017

In 2010 the premature ejaculation treatment market was estimated to be worth $684 million, according to a new research report available on companiesandmarkets.com.

30 Jun 2011

Global malaria R&D funding has received sustained growth, report says

"Annual funding for research and development (R&D) in the fight against malaria has quadrupled over 16 years, generating the strongest pipeline of potential treatments in history, according to a report on Tuesday," Reuters reports.

30 Jun 2011

Research raises questions about some generic epilepsy drugs

Generic anti-epilepsy drugs, pharmaceutical products similar to brand-name versions, save consumers billions of dollars each year, but some are different enough from branded formulations that they may not be effective, particularly if patients switch between two generic drugs, a new study by Johns Hopkins researchers suggests. A report on the study, published online and in an upcoming issue of Annals of Neurology, raises questions about whether some generic products are safe and effective when a narrow dose range separates patients from help and harm.

30 Jun 2011

Swaziland's supply of antiretroviral drugs running low

"Cash-strapped Swaziland's state hospitals have only two months' supplies of AIDS drugs, the country's health minister has told parliament in an assessment that AIDS patients and activists took as a death sentence," the Associated Press/Seattle Times reports. More than 60,000 Swazis receive antiretroviral medicine at no cost from state-run hospitals.

30 Jun 2011

Study provides novel information about clinical potential of anti-cancer antibiotics

Most of us have had a doctor prescribe an antibiotic for a stubborn bacterial infection, or for a cut that gets infected. However, prescribing an antibiotic to fight cancer? In fact, anti-cancer antibiotics have been used since the 1950s to successfully treat several forms of cancer, but often the side effects limit the duration they can be given to a patient.

30 Jun 2011

Drug companies collaborate with DNDi support to develop drug for African sleeping sickness

Researchers from Scynexis Inc. of Research Triangle Park, N.C., and Anacor Pharmaceuticals in Palo Alto, Calif., sponsored by the Drugs for Neglected Diseases initiative, on Tuesday reported in the journal PLoS Neglected Tropical Diseases that a new experimental drug kills the parasite that causes African sleeping sickness in mice and will enter human clinical trials this year, ScienceNOW reports.

30 Jun 2011

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

Scil Proteins, a private biopharmaceutical company specialized in the research, development and production of recombinant proteins, today announced that it has signed an agreement with Anabasis Pharma.

30 Jun 2011

New technology reduces stress of scheduling chemotherapy treatments

The stress of scheduling chemotherapy treatments has been substantially reduced by a new technology created and implemented by a team of researchers from the Sauder School of Business at the University of British Columbia and the BC Cancer Agency.

30 Jun 2011

Sensitivity of bladder cancer cells linked to chemotherapy and expression of miR-34a gene

Researchers at the UC Davis Cancer Center have discovered a way of sensitizing muscle-invasive bladder cancer cells so that they succumb to the toxic effects of chemotherapy. The finding adds to mounting evidence that tiny strands of RNA - called microRNA - play key roles in some of the deadliest types of cancer.

30 Jun 2011

UNC study uses optogenetics to tweak brain wiring responsible for drug addiction behaviors

Using a combination of genetic engineering and laser technology, researchers at the University of North Carolina at Chapel Hill have manipulated brain wiring responsible for reward-seeking behaviors, such as drug addiction.

30 Jun 2011